Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients
An agent that improves cardiac function without impacting systolic BP would be a welcome addition, experts say.
An agent that improves cardiac function without impacting systolic BP would be a welcome addition, experts say.
With the approval of mavacamten, patients with hypertrophic cardiomyopathy now have more options, Steve Ommen says.
In a letter to providers, the FDA advises using alternatives, if possible, saying the company has not fully addressed problems.
Mariell Jessup joins Harriette Van Spall to discuss emerging therapies and approaches to care in heart failure clinical trials.
Although the concept isn’t new, a recent study provides insight into mechanisms—and hints at novel ways to tackle residual risk.
Either intervention alone improved health in a small trial, but the best results occurred when the two were used together.
Either intervention alone improved health in a small trial, but the best results occurred when the two were used together.
Procedural complications and short-term mortality were higher with concomitant procedures, but mortality to 3 years was not.
While the tool can be helpful for ruling out ACS in those with acute chest pain, clinical judgement should always prevail.
Several surgeons told TCTMD they’re highly critical of the trend, saying it’s time for an RCT of TAVI vs SAVR in those below age 65.
The conclusion is consistent with the FDA’s review of the issue.